Edgar Filing: CLINICAL DATA INC - Form 4

CLINICAL	DATA INC											
Form 4												
April 13, 20											PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB OMB Number:	3235-0287			
Check this box				NGES IN BENEFICIAL OWNER				WNF	CRSHIP OF	Expires: Estimated a	January 31, 2005	
				SECURITIES						burden hours per		
Form 4 or Form 5 obligations may continue.response0.5See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.5												
(Print or Type	Responses)											
1. Name and Address of Reporting Person * 2. Issue FOREST LABORATORIES INC Symbol			er Name and Ticker or Trading					5. Relationship of Reporting Person(s) to Issuer				
CLINI			CAL DATA INC [CLDA]					(Check all applicable)				
				ate of Earliest Transaction nth/Day/Year)					DirectorX 10% Owner			
			04/12/2	1/12/2011				be	Officer (give title Other (specify below) below)			
									6. Individual or Joint/Group Filing(Check			
				-				_	Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting			
NEW IOR	2K, NY 10022								erson			
(City)	(State)	(Zip)	Tab	le I - Non-	Derivativ	e Secu	rities	Acquir	ed, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) ny/Year) (Instr. 8)			(D)	d (A) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amo	unt	or (D)	Price	(Instr. 3 and 4)	(Instr. 4)		
Common Stock (1)	04/12/2011			Р	27,868		A	\$ 30 (2)	0 (3)	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CLINICAL	DATA INC - Form 4
------------------------	-------------------

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	 4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
2005 Warrants	\$ 15.6	04/12/2011		Р	93,556	11/17/2005	05/17/2011	Common Stock
2006 Warrants	\$ 12.97	04/12/2011		Р	113,817	06/13/2006	12/14/2011	Common Stock
2008 Warrants	\$ 16.44	04/12/2011		Р	757,461	09/26/2008	03/26/2014	Common Stock
Series A 2009 Warrants	\$ 8.12	04/12/2011		Р	1,527,650	02/25/2009	08/25/2014	Common Stock
Series B 2009 Warrants	\$ 9.744	04/12/2011		Р	1,527,650	02/25/2009	08/25/2014	Common Stock
2017 Convertible Notes	\$ 8.1825	04/12/2011		Р	6,110,599	02/25/2009	08/25/2014 <u>(4)</u>	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
FOREST LABORATORIES INC 909 THIRD AVENUE NEW YORK, NY 10022		Х				
FL Holding C.V. C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022		Х				
FLI International, LLC C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022		Х				
Dogwood Holding Corp. C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022		Х				
		Х				

Magnolia Acquisition Corp. C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022

Signatures

/s/ David Solomon

04/13/2011

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This form is filed on behalf of Forest Laboratories, Inc. ("Forest"), FL Holding C.V. ("FL Holding"), FLI International LLC ("FLI International"), Dogwood Holding Corp. ("Dogwood") and Magnolia Acquisition Corp. ("Magnolia"), all of which are filing as members of a 10% owner group. Forest is the direct parent of FL Holding, and the indirect parent of FLI International and Dogwood. FLI

(1) International is the general partner of FL Holding, and FL Holding is the parent of Dogwood. Pursuant to the terms of the Merger Agreement, Magnolia was merged with and into Clinical Data on April 13, 2011. Prior to the merger, Magnolia was a wholly-owned subsidiary of Dogwood.

The price of each security also includes the contractual right, pursuant to a Contingent Value Rights Agreement, dated as of April 13,
 2011, by and among FL Holding, Forest and American Stock Transfer & Trust Company, LLC, as Rights Agent, to receive additional consideration of up to \$6.00 per share upon the achievement of certain milestones related to Viibryd?? (the "CVR consideration").

- (3) All of Clinical Data's outstanding securities were cancelled and/or exercised in a merger of Magnolia with and into Clinical Data on April 13, 2011 pursuant to the Merger Agreement, and converted into the right to receive the \$30.00 in cash and the CVR Consideration.
- (4) The 2017 Convertible Notes may be repaid at any time upon 90 days prior written notice. The final maturity date of the 2017 Convertible Notes is February 25, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.